LOTUS - Low dose combinations to improve stroke outcomes (ACTRN12624001279516)

The trial is testing a novel model of care employing standardised titration of low dose combinations of blood pressure (BP) and cholesterol lowering agents compared to usual care in survivors of ischaemic stroke/transient ischaemic attack (TIA). The design is open-label and will require three in-person study visits for both arms – at enrolment, week 12 and at week 26, to capture data on clinic BP, lipid levels, medication prescriptions, adherence to medication, visit frequency and adverse events. A 26-week intervention will enable assessment of the short and medium-term effects of the intervention on risk factor control, tolerability and translatability into practice.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof Geoffrey Cloud

Key inclusion data

Key Inclusion Criteria: Ischaemic stroke / TIA diagnosed by a neurologist in the last 12 weeks; Indicated for pharmacological treatment of high blood pressure; Adult aged ≥18 years; Able and willing to provide free and informed consent (on paper or electronically). Key Exclusion Criteria: Intracerebral or subarachnoid haemorrhagic stroke; Contraindication to any of the individual components of the intervention.